Open original FDA record ↗Recall record
- FDA identifier
- Z-0086-2018
- Company in FDA record
- BioMerieux SA
- FDA record creation date
- Nov 9, 2017
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Elute may become colored due to the residual presence of heme group origination from hemoglobin present in whole blood samples as well as dried spot (DBS) samples. This can potentially cause the inhibition of PCR reactions and result in an uninterpretable test result. If using an Internal Control (IC) in the extraction process the IC could potentially be inhibited as well and invalidate test results.
Source facts
- Action
- US customers were notified on 10/18/2017 via letter using 2-day Fed Ex shipment. Instructions included notifying all appropriate personnel in the laboratory or to customers if product was further distributed, refrain from using the affected product, and arrange for replacement of affected product by completing and returning the response form. It also instructed customers to contact and discuss any concerns regarding previously reported results with the appropriate Laboratory Medical Director to determine an appropriate course of action.
- Initiated
- 2017-10-18
- Root cause
- Nonconforming Material/Component
- Terminated
- 2021-08-24
- Distribution
- Distributed domestically to MD, CO, and OH.
- Recall number
- Z-0086-2018
- Recall status
- Terminated
- CDRH record ID
- 159394
- FDA record created
- 2017-11-09
- Recall event number
- 78387